Grey Wolf Therapeutics

Grey Wolf is a UK and Australian-based drug discovery and development company focused on developing novel immuno-oncology agents. The company was founded in 2017 by experienced industry professionals; Tom McCarthy (Executive Chairman; former President and CEO of Spinifex Pharmaceuticals), and Peter Joyce (CEO; former Project Leader at Vertex Pharmaceuticals). 

Rather than targeting the immune system, Grey Wolf’s approach is to directly alter tumour cells, illuminating them for attack and destruction by the immune system. The company is developing small molecules that inhibit the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which play a key role in the antigen presentation pathway. Grey Wolf has demonstrated that inhibiting these enzymes leads to modulation of the antigen repertoire within tumour cells, dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf’s unique therapeutic strategy is centred on generating a novel immune response against tumours that circumvents key resistance mechanisms to current immuno-oncology therapy, namely poor tumour recognition by T cells and T cell exhaustion.

Grey Wolf is working with leading academic and commercial drug discovery and development partners to deliver first-in-class clinical candidates against these strongly validated targets. The core team is strengthened by a network of collaborations with experts in immuno-oncology, antigen presentation and drug discovery across world leading academic institutions, including The University of Oxford, Monash University, and University of Southampton.

Grey Wolf is executing on multiple programs that are all focused on harnessing the potential of targeting ERAP as a differentiated and innovative approach to modulate tumour visibility in immuno-oncology.

Grey Wolf is a private company supported by investors committed to delivering next generation oncology therapies.